Press Releases
AVEVA to Exhibit at Drug Delivery Partnerships 2011
Aveva Drug Delivery Systems is pleased to announce that it will exhibit at Drug Delivery Partnerships on 26-28 January 2011 in Miami, ...
Press Releases
APR and Labtec enter into exclusive License Agreement with Ferrer International
APR and its development partner Labtec have entered into an exclusive licensing agreement with the leading European pharmaceutical company Ferrer Internacional (Ferrer) for the...
Press Releases
Genzyme’s Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial
Genzyme Corporation reported five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial. This sub-group analysis found that nearly 90 percent of...
News
FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules
Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release...
Research Insight
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with Betaferon® (interferon beta-1b) had a 39.3% relative reduced...
Research Insight
Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide
Sanofi-aventis announced the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of...
Techno Trends
Merck KGaA to Introduce RebiDose, the Rebif Single Use Pre-filled Pen for Treatment of Multiple Sclerosis
Merck KGaA announced the upcoming introduction of the new device RebiDose, the Rebif single use pre-filled pen, for the self-administration of Rebif (interferon beta-1a),...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
















